Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

6.60
+0.760013.01%
Post-market: 6.990.3900+5.91%18:10 EDT
Volume:146.56K
Turnover:897.88K
Market Cap:3.35M
PE:-0.06
High:6.70
Open:5.75
Low:5.54
Close:5.84
52wk High:3,840.00
52wk Low:5.25
Shares:507.40K
Float Shares:507.20K
Volume Ratio:4.07
T/O Rate:28.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-118.4105
EPS(LYR):-2,427.8177
ROE:-106.98%
ROA:-53.08%
PB:0.26
PE(LYR):0.00

Loading ...

Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis

THOMSON REUTERS
·
Sep 04

Clearmind Medicine Sets USD 1 Conversion Price for USD 696,079.50 in Notes into Common Shares

Reuters
·
Sep 03

Clearmind Medicine Starts Phase IIa CMND-100 Trial in Alcohol Use Disorder Patients

Reuters
·
Sep 01

Clearmind Reaches Key Milestone: Cmnd-100 Phase Iia NOW Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled

THOMSON REUTERS
·
Sep 01

SciSparc, Clearmind publish U.S. patent application for MDMA-PEA combination

TIPRANKS
·
Aug 24

Clearmind Medicine Says US Publishes MDMA-PEA Patent Application for PTSD Treatment

Reuters
·
Aug 24

Clearmind Advances Mdma-N-Acylethanolamines Ip for the Treatment of Ptsd Amid Rising U.S. Federal Support for Psychedelic Innovation

THOMSON REUTERS
·
Aug 24

Clearmind Advances CMND-100 into Alcohol Use Disorder Patients After Phase I/II Safety Milestone

Reuters
·
Aug 13

Clearmind Advances Cmnd-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint

THOMSON REUTERS
·
Aug 13

Clearmind Medicine Announces Positive Permeation Results for Intranasal Meai Formulation

Reuters
·
Aug 11

Clearmind Medicine reports MEAI development program permeation study results

TIPRANKS
·
Aug 11

Clearmind Medicine Reports Positive Permeation Results for Intranasal MEAI Formulation Study

Reuters
·
Aug 11

Clearmind Medicine - Intranasal Meai Shows Enhanced Nasal Retention Without Compromising Permeation

THOMSON REUTERS
·
Aug 11

Clearmind Medicine reports DSMB approves advancing Phase I/II AUD study

TIPRANKS
·
Aug 06

Clearmind Advances CMND-100 Alcohol Use Disorder Trial into Patient Testing After Phase I Safety Readout

Reuters
·
Aug 06

Clearmind Reaches Key Clinical Trial Milestone as Dsmb Unanimously Clears Progression in AUD Study

THOMSON REUTERS
·
Aug 06

Clearmind Signs LOI to Buy 51% Stake in EV Wireless Charging Firm for $2.5 Million

Reuters
·
Aug 03

Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company

THOMSON REUTERS
·
Aug 03

Clearmind Medicine - to Extend $1.50 Mln Loan at 4% Interest, Repayable in Two Years

THOMSON REUTERS
·
Aug 03

Clearmind Medicine - Deal Valued at $2.50 Mln for 51% Majority Stake

THOMSON REUTERS
·
Aug 03